S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
LON:SYNC

Syncona (SYNC) Share Price, News & Analysis

GBX 120.20
-2.00 (-1.64%)
(As of 03:32 AM ET)
Today's Range
120
121.20
50-Day Range
115
130.59
52-Week Range
105
162.20
Volume
101,673 shs
Average Volume
858,391 shs
Market Capitalization
£788.39 million
P/E Ratio
N/A
Dividend Yield
1.66%
Price Target
GBX 230

Syncona MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
91.3% Upside
GBX 230 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.15mentions of Syncona in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

SYNC stock logo

About Syncona Stock (LON:SYNC)

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

SYNC Stock Price History

SYNC Stock News Headlines

A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
Syncona (LON:SYNC) Stock Price Up 0.9%
Shortlist revealed for NED awards
A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
Syncona
Freeline Therapeutics Agrees to Buyout by Syncona
Syncona to Acquire Freeline Therapeutics
Syncona Proposes To Acquire Freeline Therapeutics
See More Headlines
Receive SYNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syncona and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Asset Management
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,208
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 230
High Stock Price Target
GBX 230
Low Stock Price Target
GBX 230
Potential Upside/Downside
+88.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-165,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-144,460,000.00
Cash Flow
GBX 104.04 per share
Book Value
GBX 179 per share

Miscellaneous

Free Float
N/A
Market Cap
£801.51 million
Optionable
Not Optionable
Beta
0.26
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Thomas Henderson (Age 57)
    Co-Founder & Non-Exec. Director
  • Dr. Martin Patrick Murphy Ph.D. (Age 55)
    Chief Exec. Officer
  • Mr. John McDonald (Age 58)
    Co-Founder
  • Mr. Rolf Kristian Berndtson Soderstrom ACA (Age 57)
    BA, Chief Financial Officer
  • Mr. Ben Woolven
    Bus. Strategy and Operations Partner
  • Dr. Christopher J. Hollowood Ph.D. (Age 48)
    CIO & Managing Partner of Syncona Investment Management Ltd.
  • Ms. Annabel Clark
    Head of Investor Relations and Communications
  • Mr. Andrew Cossar
    Gen. Counsel
  • Ms. Fenella Dernie
    Exec. Officer
  • Mr. Edward Eliot Hodgkin DPhil (Age 60)
    Managing Partner

SYNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Syncona stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syncona in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SYNC shares.
View SYNC analyst ratings
or view top-rated stocks.

What is Syncona's stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for Syncona's shares. Their SYNC share price targets range from GBX 230 to GBX 230. On average, they expect the company's share price to reach GBX 230 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price.
View analysts price targets for SYNC
or view top-rated stocks among Wall Street analysts.

How have SYNC shares performed in 2024?

Syncona's stock was trading at GBX 123.40 at the start of the year. Since then, SYNC stock has decreased by 2.6% and is now trading at GBX 120.20.
View the best growth stocks for 2024 here
.

Is Syncona a good dividend stock?

Syncona (LON:SYNC) pays an annual dividend of GBX 2 per share and currently has a dividend yield of 1.04%.
Read our dividend analysis for SYNC.

What other stocks do shareholders of Syncona own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syncona investors own include Rexahn Pharmaceuticals (REXN), Barrick Gold (ABX), Agnico Eagle Mines (AEM), Franco-Nevada (FNV), Goldex Resources (GDX), VanEck Gold Miners ETF (GDX), Goldcorp (GG), Barrick Gold (GOLD) and Northern Dynasty Minerals (NAK).

How do I buy shares of Syncona?

Shares of SYNC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SYNC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners